Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Coronavirus Disease 2019 (COVID-19) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Coronavirus Disease 2019 (COVID-19) vaccine overview
Vaccine candidate is under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant and coronavirus disease 2019 (covid-19) pneumonia. It is administered through intramuscular route.
China National Biotec Group overview
China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corp, is a manufacturer and distributor of vaccines, therapeutic products, and diagnostic reagents. The company develops biological products for disease prevention, therapeutic and diagnostic use. Its products include live vector-based anti-HIV vaccine; hepatitis B vaccine for therapeutic use; shigella conjugate vaccine; and trivalent rotavirus vaccine, among others. CNBG distributes its products through its network of marketing and sales. The company also operates various biological product institutes. CNBG is headquartered in Beijing, China.
For a complete picture of Coronavirus Disease 2019 (COVID-19) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
